- Home
- Results news
- Archit Organosys
- Q2 FY27 results
Archit Organosys Q2 FY27 results: net profit flat at ₹1.54 crore, revenue up 94.7%
Archit Organosys Ltd reported standalone Q2 FY27 revenue of ₹63.99 crore, up 94.7% from Q2 FY26. Profit before tax was ₹1.90 crore and net profit was ₹1.54 crore, with basic EPS of ₹0.75 and EBITDA margin of 4.9%.
Key points
- Revenue rose to ₹63.99 crore in Q2 FY27, up 94.7% from ₹32.86 crore in Q2 FY26 and 72.6% from ₹37.08 crore in Q1 FY27.
- EBITDA was ₹3.16 crore, up 17.0% from ₹2.70 crore a year ago but down 6.2% from ₹3.37 crore in Q1 FY27.
- Net profit was ₹1.54 crore, unchanged from Q2 FY26 and up 6.2% from ₹1.45 crore in Q1 FY27; basic EPS was ₹0.75.
- H1 FY27 revenue was ₹101.08 crore, up 53.0% from H1 FY26, while net profit fell to ₹2.99 crore from ₹3.58 crore.
- Total assets were ₹131.07 crore and total equity was ₹79.23 crore as of 30 September 2026; borrowings were ₹7.21 crore and cash was ₹1.08 crore.
How did Archit Organosys perform in Q2 FY27?
Archit Organosys reported standalone Q2 FY27 revenue of ₹63.99 crore for the July–September 2026 quarter, up 94.7% from ₹32.86 crore in Q2 FY26 and 72.6% from ₹37.08 crore in Q1 FY27. Total income was ₹64.63 crore, up 88.3% year on year and 71.5% from the previous quarter. The results are standalone; no consolidated figures were provided in the supplied information.
EBITDA was ₹3.16 crore in Q2 FY27, compared with ₹2.70 crore in Q2 FY26 and ₹3.37 crore in Q1 FY27. The EBITDA margin was 4.9%, down 3.3 percentage points from 8.2% a year ago and 4.2 percentage points from 9.1% in the previous quarter. Profit before tax was ₹1.90 crore, compared with ₹1.97 crore in Q2 FY26 and ₹2.03 crore in Q1 FY27.
Net profit was ₹1.54 crore in Q2 FY27, unchanged from ₹1.54 crore in Q2 FY26 and up 6.2% from ₹1.45 crore in Q1 FY27. Basic EPS was ₹0.75, compared with ₹0.75 in Q2 FY26 and ₹0.71 in Q1 FY27. The profit margin was 2.4%, compared with 4.7% a year ago and 3.9% in the previous quarter.
| ₹ crore | Q2 FY27 | Q1 FY27 | Q2 FY26 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 63.99 | 37.08 | 32.86 | +94.7% | +72.6% |
| Other income | 0.64 | 0.60 | 1.46 | −56.2% | +6.7% |
| Total expenses | 62.73 | 35.66 | 32.35 | +93.9% | +75.9% |
| EBITDA | 3.16 | 3.37 | 2.70 | +17.0% | −6.2% |
| EBITDA margin | 4.9% | 9.1% | 8.2% | −3.3 pp | −4.2 pp |
| Profit before tax | 1.90 | 2.03 | 1.97 | −3.6% | −6.4% |
| Tax | 0.35 | 0.58 | 0.43 | −18.6% | −39.7% |
| Net profit | 1.54 | 1.45 | 1.54 | +0.0% | +6.2% |
| EPS (₹) | 0.75 | 0.71 | 0.75 | +0.0% | +5.6% |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in Archit Organosys' costs and profit?
Total expenses were ₹62.73 crore in Q2 FY27, up 93.9% from ₹32.35 crore in Q2 FY26 and 75.9% from ₹35.66 crore in Q1 FY27. Cost of materials was ₹10.92 crore, up ₹1.02 crore from the year-ago quarter, while employee cost fell ₹0.12 crore and finance costs fell ₹0.29 crore. Depreciation was unchanged at ₹1.52 crore, and other expenses rose ₹0.19 crore.
Other income was ₹0.64 crore, down ₹0.82 crore from ₹1.46 crore in Q2 FY26, while tax expense was ₹0.35 crore, down ₹0.08 crore from ₹0.43 crore. There was no exceptional item in either quarter. Against Q1 FY27, cost of materials fell ₹6.76 crore, other expenses fell ₹1.72 crore and finance costs fell ₹0.06 crore, while employee cost and depreciation rose by ₹0.02 crore each. The filing does not state why the quarterly movements occurred.
| ₹ crore | Q2 FY27 | Q2 FY26 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 10.92 | 9.90 | +1.02 | +10.3% |
| Employee cost | 1.82 | 1.94 | −0.12 | −6.2% |
| Finance costs | 0.38 | 0.67 | −0.29 | −43.3% |
| Depreciation | 1.52 | 1.52 | 0 | +0.0% |
| Other expenses | 4.77 | 4.58 | +0.19 | +4.1% |
| Total expenses | 62.73 | 32.35 | +30.38 | +93.9% |
| Other income | 0.64 | 1.46 | −0.82 | −56.2% |
| Tax | 0.35 | 0.43 | −0.08 | −18.6% |
Source: Company's results filing (XBRL).
How did the first half of FY27 go?
In the first half of FY27, Archit Organosys reported standalone revenue of ₹101.08 crore, up 53.0% from ₹66.06 crore in H1 FY26. Total income was ₹102.32 crore, up 49.4% from ₹68.51 crore. The company’s H1 FY27 results were unaudited, and the board approved them on 4 November 2026.
Profit before tax in H1 FY27 was ₹3.93 crore, down 21.7% from ₹5.02 crore in H1 FY26. Net profit was ₹2.99 crore, down 16.5% from ₹3.58 crore, and basic EPS was ₹1.46, compared with ₹1.74 in the year-ago period. Revenue therefore rose while profit declined during the first half.
| ₹ crore | H1 FY27 | H1 FY26 | Change |
|---|---|---|---|
| Revenue from operations | 101.08 | 66.06 | +53.0% |
| Profit before tax | 3.93 | 5.02 | −21.7% |
| Net profit | 2.99 | 3.58 | −16.5% |
| EPS (₹) | 1.46 | 1.74 | −16.1% |
Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
As of 30 September 2026, total assets were ₹131.07 crore, compared with ₹126.67 crore at 31 March 2026. Total equity was ₹79.23 crore against ₹76.23 crore, while borrowings declined to ₹7.21 crore from ₹24.66 crore and cash was ₹1.08 crore compared with ₹1.37 crore. Inventories were ₹2.91 crore, trade receivables ₹39.44 crore and trade payables ₹37.74 crore.
H1 FY27 operating cash flow was ₹8.56 crore, compared with ₹3.44 crore in H1 FY26. Investing cash flow was ₹9.51 crore against an outflow of ₹3.03 crore, while financing cash flow was an outflow of ₹18.37 crore compared with an outflow of ₹0.41 crore. Capital expenditure was ₹0.35 crore in H1 FY27, against ₹0.69 crore in H1 FY26.
| ₹ crore | As of 30 September 2026 | As of 31 March 2026 |
|---|---|---|
| Total assets | 131.07 | 126.67 |
| Total equity | 79.23 | 76.23 |
| Borrowings | 7.21 | 24.66 |
| Cash and equivalents | 1.08 | 1.37 |
| Inventories | 2.91 | 2.95 |
| Trade receivables | 39.44 | 24.55 |
Source: Company's results filing (XBRL).
| ₹ crore | H1 FY27 | H1 FY26 |
|---|---|---|
| Cash from operations | 8.56 | 3.44 |
| Cash from investing | 9.51 | −3.03 |
| Cash from financing | −18.37 | −0.41 |
| Capital expenditure | 0.35 | 0.69 |
Source: Company's results filing (XBRL).
How has Archit Organosys done over the last 8 quarters?
Revenue reached ₹63.99 crore in Q2 FY27, the highest level in the eight-quarter trend shown, after ₹37.08 crore in Q1 FY27. Revenue was lowest at ₹25.87 crore in Q3 FY25. The company has recorded year-on-year revenue growth in each of the last two quarters.
How did other Commodity Chemicals companies do?
Among 23 other Commodity Chemicals companies that had filed for the quarter as of 5 November 2026, the median revenue growth was 19.1%. Of those peers, 21 grew more slowly than Archit Organosys and 2 grew faster. Twenty-one peers reported higher profit, from a profit comparison covering 27 peers.
| Archit Organosys revenue growth (YoY) | +94.7% |
|---|---|
| Median of 23 other Commodity Chemicals companies | +19.1% |
| Companies with slower revenue growth than Archit Organosys | 21 of 23 |
| Companies with faster revenue growth than Archit Organosys | 2 of 23 |
| Companies whose net profit rose | 21 of 27 |
Source: Filed results (XBRL) of the industry's companies.
Quick answers
What was Archit Organosys' revenue in Q2 FY27?
Revenue from operations was ₹63.99 crore, up 94.7% from ₹32.86 crore in Q2 FY26 (standalone).
Did Archit Organosys make a profit in Q2 FY27?
Yes. Net profit was ₹1.54 crore, against a net profit of ₹1.54 crore in Q2 FY26.
What was Archit Organosys' EPS in Q2 FY27?
Basic earnings per share were ₹0.75, against ₹0.75 in Q2 FY26.
When did Archit Organosys announce its Q2 FY27 results?
On 4 November 2026, in a filing to the BSE.
Sources
- Board Meeting Intimation for Intimation Of Board Meeting (BSE, 29 October 2026) · PDF
- Board Meeting Outcome for Outcome Of Board Meeting (BSE, 4 November 2026) · PDF
- Results: Un-Audited Financial Result For Quarter And Half Year Ended On September 30, 2026. (BSE, 4 November 2026) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.